

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities of the Company.



Shanghai Conant Optical Co., Ltd.
上海康耐特光學科技集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2276)

VOLUNTARY ANNOUNCEMENT –
THE IMPACT OF THE U.S. TARIFF ON THE COMPANY'S BUSINESS

This announcement is made voluntarily by Shanghai Conant Optical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”).

The recent adjustment of the U.S. tariff policy has aroused widespread concern in the market. As a global resin spectacle lens manufacturer and sales services provider, the Company has always adhered to the principle of high transparency to customers and investors. Therefore, the Company hereby announces the assessment of the board (the “**Board**”) of directors (the “**Directors**”) of the Company and its corresponding strategies to deal with the impact of the U.S. tariff adjustment:

THE U.S. MARKET HAS A LOWER END-PRICE SENSITIVITY, WHICH IMPOSES A LOWER ACTUAL IMPACT ON THE COMPANY'S PRODUCTS

Resin spectacle lens products are covered by Medicare in the U.S., and the industry has a higher pipeline markup (with end retail price being approximately several times the ex-factory price). Consumer sensitivity to end price is limited and the market demand for resin lens products as medical devices is relatively stable. The Board believes that the actual impact of the tariff cost passed through to the end consumer is relatively smaller.

THE SUPPLY CHAIN PATTERN OF GLOBAL RESIN SPECTACLE LENSES PRODUCTS IS STABLE WITH LIMITED SUBSTITUTIONS

Currently, the world's major producers of resin lenses are located in China and Southeast Asia, and it is difficult for U.S. customers to find alternative sources of supply of the same scale in the short term. The Company's production bases in China and Japan have mature production capacity and stable supply capability, which can effectively protect the demand of the Company's customers.

THE IMPACT OF THE U.S. TARIFF POLICY IS MANAGEABLE AND HAS LIMITED IMPACT ON THE OVERALL REVENUE OF THE COMPANY

Based on the conservative calculations by the Board and after considering the most prudent scenario, assuming that the Company bears 50% (i.e. 17%) of the new tariffs and combining with the U.S. market's share of the Company's overall revenue last year (i.e. 13%), the direct impact on the full year's revenue is initially estimated to be approximately 2.2%.

HIGH GROWTH IN MARKETS OUTSIDE THE U.S. HAS BEEN EFFECTIVELY HEDGING RISKS

The Board is of the view that the Company's markets outside of the U.S., including its domestic business, will maintain a strong growth momentum in the financial year ending 31 December 2025, and as a result, the marginal impact of the U.S. tariff policy on overall revenue is expected to be less than 2.2%.

COST STRUCTURE IS OPTIMIZED THROUGH SYNERGETIC GLOBAL CAPACITY DEPLOYMENT

The Company is actively leveraging the synergetic network of factories in China, Southeast Asia and Japan to flexibly deploy production capacity as per its policy and market demand, which will further enhance supply chain resilience and achieve cost efficiency optimisation.

BUSINESS UPDATE FOR THE FIRST QUARTER OF 2025

Looking back at the performance of the Company for the first quarter of 2025, the Company's revenues remained at a higher level as the Company's product development and manufacturing divisions continued to grow and the number of orders from customers was in line with the Company's expectations. The performance of the Company for the first quarter is expected to remain in a satisfactory position.

The Company has always responded to market fluctuations with a global perspective, and has continued to enhance its anti-risk capability through diversified deployment and technological upgrades. We will closely track policy trends and maintain transparent communication with our partners to ensure service stability and long-term value delivery.

By order of the Board

Shanghai Conant Optical Co., Ltd.

Fei Zhengxiang

Executive Director and Chairman of the Board

Hong Kong, 7 April 2025

As at the date of this announcement, the Board comprises Mr. Fei Zhengxiang, Mr. Zheng Yuhong, Mr. Xia Guoping, Mr. Chen Junhua, Mr. Wang Chuanbao and Ms. Cao Xue as executive directors; Ms. Zhao Xiaoyun and Mr. Tian Kehan as non-executive directors; and Dr. Xiao Fei, Mr. Chen Yi, Dr. Wu Ying and Mr. Jin Yiting as independent non-executive directors.